How to Build a Biotech Portfolio That Doesn’t Blow Up | Ep. 738

Survive volatile markets and scale with conviction.

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we unpack a simple but powerful system for managing biotech portfolios with more discipline, less drift, and greater clarity. In a market where trial data can get drowned out by macro volatility, investors need more than conviction, they need structure. Last week we discussed how to implement macro hedging. This week ee walk through a four-bucket portfolio design that organizes exposure by risk, stage, and role. From core anchors to asymmetric moonshots, every position gets a lane. We also show how to use fast scoring methods to size positions and rotate capital with logic. Paired with a macro hedge, this system helps you survive the cycle, stay flexible, and explain your strategy with confidence.

We are now publishing 7x per week according to the following cadence:

• Mondays: Stocks

• Tuesdays: Biotech

• Wednesdays: Podcast

• Thursdays: Markets

• Fridays: News

• Saturdays: Podcast

• Sundays: Strategy

We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.

SUBSCRIBE TO PODCAST HERE:

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

Enough shilling for the day, lots to cover this week, let's get started!

The Real Reason Portfolios Fail

Biotech investing is often framed around one question: do you believe in the science? Investors spend hours dissecting mechanisms of action, debating clinical trial design, and analyzing biomarkers. These steps matter. But focusing only on biology creates a dangerous blind spot.

The real challenge in biotech investing is not picking winners. It is surviving long enough to let those winners play out. That requires structure.

Structure means knowing what role each position plays. It means sizing exposure based on risk, stage, and probability, not just conviction. Without it, portfolios become a patchwork of good ideas with no system behind them. When volatility spikes, these portfolios are the first to unravel. The investor sells the wrong name, doubles down on the wrong setup, or freezes entirely. What looks like a science problem is often a portfolio construction problem.

This has become even more true in today’s market. Inflation, rate policy, credit spreads, and liquidity all influence biotech performance as much as clinical data. A flawless readout can get ignored if macro is collapsing. A weak readout can rally on short covering if capital is flowing. In this environment, the difference between compounding and liquidation is not scientific insight. It is how you build the book.

A Two-Layered Defense: Portfolio Design Meets Macro Hedge

Biotech investing requires more than scientific conviction. It requires a system.

Today we introduce a portfolio design framework that helps investors organize their biotech exposure with discipline. Instead of chasing catalysts or hoping for re-ratings, the structure brings clarity to how each position fits. It creates lanes for stability, upside, growth, and optionality. By defining role and sizing by stage and risk, the portfolio becomes easier to manage and more resilient through volatility.

This design complements the macro hedge system outlined in the prior essay. While portfolio structure manages internal exposure, macro hedging defends against external shocks. Tools like gold, credit spreads, and volatility overlays provide a shield when the broader market turns risk-off.

The combination creates a two-layered defense.

One layer builds conviction around individual names. The other protects against forces that have nothing to do with biology.

Together, they create a more stable foundation, one that allows investors to stay in the game long enough to let the science work.

If you missed last week’s write-up on macro hedging see below for link.

Four Buckets, One Framework